nirogacestat,lenalidomide,teclistamab,daratumumab,pomalidomide,bortezomib
takeda,springworks therapeutics,janssen,genmab,bms
['majestec-2', 'enhance,(-enhance 3),(-enhance-3),(-enhance3),(-enhanced),(-enahnces),(-enhancem),(-enhancer)', 'lenalidomide', 'darzalex', ' lena', 'majestec,(-majestec-1),(-majestec1),(-majestec 1),(-majestec-3),(-majestec3),(-majestec 3),(-majestec-i),(-majestec i),(-majesteci)', 'revlimid']
majestec-2 ph 1b study of the tecvayli-darzalex-revlimid combination, the first fully immune-based triplet in rrmm. infections common but mostly low grade, 93.5% overall response in 31 patients. this combination will next be tested at an earlier line of therapy. #ash2022 
Multiple Myeloma Research Foundation - Accelerating the development of next generation #myeloma treatments to extend patient’s lives, and lead to a cure.